Final Redaction.pdf (1.26 MB)

Redacted study protocol. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma

dataset

posted on 2021-05-12, 09:03 authored by Josep Tabernero, Yung-Jue Bang, Eric Van Cutsem, Charles S Fuchs, Yelena Yuriy Janjigian, Pooja Bhagia, Kan Li, David Adelberg, Shu Kui Qin

Redacted study protocol

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma

Funding

Merck

History

Usage metrics

Read the peer-reviewed publication

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma

Future Science Group

Keywords

chemotherapy HER2-negative gastric cancer gastroesophageal junction cancer adenocarcinoma immunotherapy pembrolizumab first-line therapy Solid Tumours

Licence

CC BY-NC-ND 4.0